Cargando…
Association of IgG1 Antibody Clearance with FcγRIIA Polymorphism and Platelet Count in Infliximab-Treated Patients
The FcγRIIA/CD32A is mainly expressed on platelets, myeloid and several endothelial cells. Its affinity is considered insufficient for allowing significant binding of monomeric IgG, while its H131R polymorphism (histidine > arginine at position 131) influences affinity for multimeric IgG2. Platel...
Autores principales: | Thibault, Gilles, Paintaud, Gilles, Sung, Hsueh Cheng, Lajoie, Laurie, Louis, Edouard, Desvignes, Celine, Watier, Hervé, Gouilleux-Gruart, Valérie, Ternant, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199937/ https://www.ncbi.nlm.nih.gov/pubmed/34205175 http://dx.doi.org/10.3390/ijms22116051 |
Ejemplares similares
-
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
por: Ducourau, Emilie, et al.
Publicado: (2011) -
Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development
por: Dumet, Christophe, et al.
Publicado: (2019) -
Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review
por: Ramdani, Yanis, et al.
Publicado: (2022) -
Harnessing Fc/FcRn Affinity Data from Patents with Different Machine Learning Methods
por: Dumet, Christophe, et al.
Publicado: (2023) -
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
por: Mulleman, Denis, et al.
Publicado: (2011)